Discussion
A new first-in-class treatment for Parkinson’s disease, designed to get past the brain’s protective barrier, was shown to be safe and well-tolerated in an early clinical trial, and to have “robust [central nervous system] exposure.” That’s according to new data from the Phase 1 trial, which involved both patients…
